Hudson Executive Capital’s Acorda Therapeutics ACOR Stock Holding History

Hudson Executive Capital’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,973	Closed	-$31.1M	–	8
2018 Q1	$31.1M	Hold	10,973	–	–	9.19%	5
2017 Q4	$28.2M	Buy	10,973 +3,527	+47%	+$10M	13.56%	5
2017 Q3	$21.1M	Buy	7,446 +1,004	+16%	+$2.64M	10.63%	4
2017 Q2	$15.2M	Buy	+6,442	New	+$12.8M	7%	5

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hudson Executive Capital's ACOR Position: Q2 2018 in Review

Hudson Executive Capital sold out of Acorda Therapeutics (ACOR) in Q2 2018, closing a stake of 10,973 shares — an estimated $31.1M sold.

Hudson Executive Capital first reported a position in ACOR in Q2 2017 and held it in 4 quarters. The position peaked at $31.1M in Q1 2018. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2018.

Hudson Executive Capital reported no remaining Acorda Therapeutics position as of Q2 2018 after selling out during the quarter.
Hudson Executive Capital sold 10,973 Acorda Therapeutics shares in Q2 2018, an estimated $31.1M.
Hudson Executive Capital first reported a position in Acorda Therapeutics in Q2 2017 and held it in 4 quarters.
Hudson Executive Capital's Acorda Therapeutics position peaked at $31.1M in Q1 2018.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2018.

Based on Hudson Executive Capital's 13F filing for Q2 2018, filed 14 Aug 2018.